Learn about the genes Color analyzes.
The genes we analyze depends on the version of Color you use.
For people who want a more complete understanding of their genes and health, and for those who have a personal or family history of conditions covered. Includes all genes currently analyzed by Color.
Color Extended: The most relevant genes for common hereditary cancers
Gene | Breast | Ovarian | Uterine | Colorectal | Melanoma | Pancreatic | Stomach | Prostate* |
---|---|---|---|---|---|---|---|---|
BRCA1 |
|
|
|
|
||||
BRCA2 |
|
|
|
|
|
|||
MLH1 |
|
|
|
|
|
|
||
MSH2 |
|
|
|
|
|
|
||
MSH6 |
|
|
|
|
|
|||
PMS2* |
|
|
|
|
||||
EPCAM* |
|
|
|
|
|
|
||
APC |
|
|
|
|||||
MUTYH |
|
|||||||
MITF* |
|
|||||||
BAP1 |
|
|||||||
CDKN2A |
|
|
||||||
CDK4* |
|
|||||||
TP53 |
|
|
|
|
|
|
|
|
PTEN |
|
|
|
|
||||
STK11 |
|
|
|
|
|
|
||
CDH1 |
|
|
||||||
BMPR1A |
|
|
|
|||||
SMAD4 |
|
|
|
|||||
GREM1* |
|
|||||||
POLD1* |
|
|||||||
POLE* |
|
|||||||
PALB2 |
|
|
|
|||||
CHEK2 |
|
|
|
|||||
ATM |
|
|
|
|||||
BARD1 |
|
|||||||
BRIP1 |
|
|
||||||
RAD51C |
|
|||||||
RAD51D |
|
|||||||
* CDK4: analysis is limited to chr12:g.58145429-58145431 (codon 24). EPCAM: analysis is limited to deletions that minimally encompass the 3’ end of the gene including exons 8 and/or 9. GREM1: analysis is limited to duplications that overlap the upstream regulatory region. MITF: analysis is limited to chr3:g.70014091 (including c.952G>A). PMS2: variants of uncertain significance are not reported for exons 12-15. Analysis excludes three variants commonly observed in the pseudogene PMS2CL: c.2182_2184delinsG, c.2243_2246delAGAA and deletion of exons 13-14 (chr7:g.6015768_6018727del). POLD1: analysis is limited to chr19:g.50909713 (including c.1433G>A). POLE: analysis is limited to chr12:g.133250250 (including c.1270C>G). |
Color Extended: The most relevant genes for common hereditary heart conditions
Gene | Cardiomyopathies | Arrhythmias | Arteriopathies | Familial Hypercholesterolemia |
---|---|---|---|---|
ACTA2 |
|
|||
ACTC1 |
|
|||
APOB* |
|
|||
COL3A1 |
|
|||
DSC2 |
|
|||
DSG2 |
|
|||
DSP |
|
|||
FBN1 |
|
|||
GLA |
|
|||
KCNH2* |
|
|||
KCNQ1* |
|
|||
LDLR |
|
|||
LMNA |
|
|||
MYBPC3* |
|
|||
MYH7* |
|
|||
MYH11 |
|
|||
MYL2 |
|
|||
MYL3 |
|
|||
PCSK9 |
|
|||
PKP2 |
|
|||
PRKAG2* |
|
|||
RYR2 |
|
|||
SCN5A |
|
|||
SMAD3 |
|
|||
TGFBR1* |
|
|||
TGFBR2 |
|
|||
TMEM43 |
|
|||
TNNI3 |
|
|||
TNNT2 |
|
|||
TPM1 |
|
|||
* APOB: analysis is limited to chr2:g.21229159_21229161 (codon 3527). KCNH2: exon 4 and 14 are not analyzed. KCNQ1: exon 1 is not analyzed. MYBPC3: exon 11 is not analyzed. MYH7: variants of uncertain significance are not reported for exon 27. PRKAG2: exon 5 is not analyzed. TGFBR1: exon 1 is not analyzed. |
Color Extended: Genes associated with some commonly prescribed medications
Gene | Star alleles and variants analyzed |
---|---|
CYP1A2 | *1F, *1J, *1K |
CYP2D6 | *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *14A, *14B, *15, *17, *19, *29, *35, *36, *41, *xN |
CYP2C19 | *2, *3, *4A, *4B, *10, *17 |
CYP2C9 | *2, *3, *4, *5, *6, *8, *11 |
CYP3A4 | *1B, *22 |
CYP3A5 | *3, *6, *7 |
CYP4F2 | *3 |
DPYD | *2A, *13 |
F5 | rs6025 (Leiden) |
IFNL3 | rs12979860 |
NUDT15 | rs116855232 |
SLCO1B1 | rs4149056 |
TPMT | *2, *3A, *3C, *4 |
VKORC1 | rs9923231 |
Available through employers and healthcare providers. Includes only the 10 most actionable genes, recognized by the CDC as important for public health, and genes related to medication reaction.
Color Standard: Cancer genes recognized by the CDC as important for public health
Gene | Breast | Ovarian | Uterine | Colorectal | Melanoma | Pancreatic | Stomach | Prostate* |
---|---|---|---|---|---|---|---|---|
BRCA1 |
|
|
|
|
||||
BRCA2 |
|
|
|
|
|
|||
MLH1 |
|
|
|
|
|
|
||
MSH2 |
|
|
|
|
|
|
||
MSH6 |
|
|
|
|
|
|||
PMS2* |
|
|
|
|
||||
EPCAM* |
|
|
|
|
|
|
||
* EPCAM: analysis is limited to deletions that minimally encompass the 3’ end of the gene including exons 8 and/or 9. PMS2: variants of uncertain significance are not reported for exons 12-15. Analysis excludes three variants commonly observed in the pseudogene PMS2CL: c.2182_2184delinsG, c.2243_2246delAGAA and deletion of exons 13-14 (chr7:g.6015768_6018727del). |
Color Standard: Familial Hypercholesterolemia (FH) genes recognized by the CDC as important for public health
Gene | Familial Hypercholesterolemia (FH) |
---|---|
APOB* |
|
LDLR |
|
PCSK9 |
|
*APOB: analysis is limited to chr2:g.21229159_21229161 (codon 3527). |
Color Standard: Genes associated with some commonly prescribed medications
Gene | Star alleles and variants analyzed |
---|---|
CYP1A2 | *1F, *1J, *1K |
CYP2D6 | *2, *3, *4, *4N *5, *6, *7, *8, *9, *10, *11, *12, *14A, *14B, *15, *17, *19, *29, *35, *36, *41, *xN |
CYP2C19 | *2, *3, *4A, *4B, *10, *17 |
CYP2C9 | *2, *3, *4, *5, *6, *8, *11 |
CYP3A4 | *1B, *22 |
CYP3A5 | *3, *6, *7 |
CYP4F2 | *3 |
DPYD | *2A, *13 |
F5 | rs6025 (Leiden) |
IFNL3 | rs12979860 |
NUDT15 | rs116855232 |
SLCO1B1 | rs4149056 |
TPMT | *2, *3A, *3C, *4 |
VKORC1 | rs9923231 |
For those who would like to understand hereditary cancer risk only.
Color Hereditary Cancer: The most relevant genes for common hereditary cancers
Gene | Breast | Ovarian | Uterine | Colorectal | Melanoma | Pancreatic | Stomach | Prostate* |
---|---|---|---|---|---|---|---|---|
BRCA1 | ||||||||
BRCA2 | ||||||||
MLH1 | ||||||||
MSH2 | ||||||||
MSH6 | ||||||||
PMS2* | ||||||||
EPCAM* | ||||||||
APC | ||||||||
MUTYH | ||||||||
MITF* | ||||||||
BAP1 | ||||||||
CDKN2A | ||||||||
CDK4* | ||||||||
TP53 | ||||||||
PTEN | ||||||||
STK11 | ||||||||
CDH1 | ||||||||
BMPR1A | ||||||||
SMAD4 | ||||||||
GREM1* | ||||||||
POLD1* | ||||||||
POLE* | ||||||||
PALB2 | ||||||||
CHEK2 | ||||||||
ATM | ||||||||
BARD1 | ||||||||
BRIP1 | ||||||||
RAD51C | ||||||||
RAD51D | ||||||||
* CDK4: analysis is limited to chr12:g.58145429-58145431 (codon 24). EPCAM: analysis is limited to deletions that minimally encompass the 3’ end of the gene including exons 8 and/or 9. GREM1: analysis is limited to duplications that overlap the upstream regulatory region. MITF: analysis is limited to chr3:g.70014091 (including c.952G>A). PMS2: variants of uncertain significance are not reported for exons 12-15. Analysis excludes three variants commonly observed in the pseudogene PMS2CL: c.2182_2184delinsG, c.2243_2246delAGAA and deletion of exons 13-14 (chr7:g.6015768_6018727del). POLD1: analysis is limited to chr19:g.50909713 (including c.1433G>A). POLE: analysis is limited to chr12:g.133250250 (including c.1270C>G). |